Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges

This paper offers a review and recommendations for clinicians working with patients interested in discontinuing opioid agonist treatment. As buprenorphine/naloxone has gained widespread acceptance for opioid addiction, many treatment providers and patients have a range of hopes and expectations about its optimal use. A surprising number assume buprenorphine/naloxone is primarily useful as a medication to transition off illicit opioid use, and success is partially defined by discontinuing the medication. Despite accumulating evidence that a majority of patients will need to remain on medication to preserve their gains, clinicians often have to address a patient's fervent desire to taper. Using the concept of “recovery capital,” our review addresses (1) the appropriate duration of opioid agonist treatment, (2) risks associated with discontinuing, (3) a checklist that guides the patient through self-assessment of the wisdom of discontinuing opioid agonist treatment, and (4) shared decision making about how to proceed.

[1]  R. Weiss,et al.  Discontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know? , 2020, The American journal of psychiatry.

[2]  M. Olfson,et al.  Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder. , 2019, The American journal of psychiatry.

[3]  A. Leshner,et al.  The Effectiveness of Medication-Based Treatment for Opioid Use Disorder , 2019 .

[4]  Shannon C Miller,et al.  The ASAM Principles of Addiction Medicine , 2018 .

[5]  M. Olfson,et al.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. , 2018, Journal of substance abuse treatment.

[6]  N. Volkow,et al.  Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative. , 2018, JAMA.

[7]  Benjamin P Linas,et al.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.

[8]  P. Krajči,et al.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial , 2017, JAMA psychiatry.

[9]  L. Degenhardt,et al.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies , 2017, British Medical Journal.

[10]  C. Green,et al.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. , 2016, Drug and alcohol dependence.

[11]  Rosalie Liccardo Pacula,et al.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. , 2015, The Milbank quarterly.

[12]  S. Back,et al.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. , 2015, Journal of substance abuse treatment.

[13]  T. Borkman,et al.  Elements that define recovery: the experiential perspective. , 2014, Journal of studies on alcohol and drugs.

[14]  O. Bukstein.  The Spirit of Motivational Interviewing , 2014 .

[15]  Joshua M Sharfstein,et al.  Confronting the stigma of opioid use disorder--and its treatment. , 2014, JAMA.

[16]  Howard S. Smith,et al.  Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. , 2012, Pain physician.

[17]  S. Higgins,et al.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. , 2011, Drug and alcohol dependence.

[18]  R. Newman.  Comparing buprenorphine 'tapers'--to what end? , 2009, Addiction.

[19]  A. Laudet,et al.  Recovery Capital as Prospective Predictor of Sustained Recovery, Life Satisfaction, and Stress Among Former Poly-Substance Users , 2008, Substance use & misuse.

[20]  H. Kleber.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options , 2007, Dialogues in clinical neuroscience.

[21]  Zoran Brkanac,et al.  Genetic Determinants of Addiction to Opioids and Cocaine , 2005, Harvard review of psychiatry.

[22]  J. Bell,et al.  Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. , 2003, Drug and alcohol dependence.

[23]  H. W. Clark,et al.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. , 2000, JAMA.

[24]  R. Granfield,et al.  Coming Clean: Overcoming Addiction Without Treatment , 1999 .

[25]  V. Dole.  On federal regulation of methadone treatment. , 1995, JAMA.

[26]  K. Preston,et al.  Acute administration of buprenorphine in humans: partial agonist and blockade effects. , 1995, The Journal of pharmacology and experimental therapeutics.

[27]  J. Zweben,et al.  Methadone maintenance in the treatment of opioid dependence. A current perspective. , 1990, The Western journal of medicine.

[28]  J. Sorensen,et al.  Misunderstandings about methadone. , 1988, Journal of psychoactive drugs.

[29]  J. Milby,et al.  Methadone Maintenance to Abstinence: How Many Make It? , 1988, The Journal of nervous and mental disease.

[30]  S. B. Sells.  Methadone Maintenance in Perspective , 1977 .

[31]  E. Quinn,et al.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine. , 2017, Drug and alcohol dependence.

[32]  Master Textbook,et al.  TIP 47: Substance Abuse: Clinical Issues in Intensive Outpatient Treatment , 2016 .

[33]  W. White,et al.  Recovery Capital: A Primer for Addictions Professionals , 2008 .

[34]  L. Amato,et al.  Methadone at tapered doses for the management of opioid withdrawal. , 2003, The Cochrane database of systematic reviews.

[35]  J. Sorensen,et al.  Withdrawal from methadone maintenance. Impact of a tapering network support program. , 1992, Journal of substance abuse treatment.

[36]  J. Sorensen,et al.  Bridges and barriers to recovery: clinical observations from an opiate recovery project. , 1987, Journal of substance abuse treatment.

[37]  D. Lipton,et al.  "It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment. , 1985, The International journal of the addictions.